Linked Life Data

16799777

Source:http://linkedlifedata.com/resource/pubmed/id/16799777

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2006-9-13
pubmed:abstractText
The strong link between the bowel and the osteo-articular system is suggested by many clinical and experimental observations. However, the therapeutic approach is still empirical. For symptomatic therapy it is better to favour the use of steroids and avoid non-steroidal anti-inflammatory drugs because they may induce intestinal ulcerations and can activate inflammatory bowel disease. Second line drugs (sulfasalazine, methotrexate, azathioprine, cyclosporine and leflunomide) should be used for selected indications. In some cases (severe spondylitis, severe and persistent enthesopathy) anti-TNF-alpha agents (infliximab) should be considered as first line therapy. In all cases it is mandatory to select the best therapeutic option for each individual patient, considering that the optimal treatment of bowel inflammation may induce "per se" a remission of the musculo-skeletal manifestations.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0172-8172
pubmed:author
pubmed:issnType
Print
pubmed:volume
26
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
953-8
pubmed:meshHeading
pubmed:year
2006
pubmed:articleTitle
The treatment of the rheumatological manifestations of the inflammatory bowel diseases.
pubmed:affiliation
Unit of Rheumatology, Department of Clinical and Experimental Medicine, University of Ferrara, Corso Giovecca 203 44100, Ferrara, Italy. melipadovan@yahoo.it
pubmed:publicationType
Journal Article, Review